{
    "info": {
        "nct_id": "NCT04892446",
        "official_title": "A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma",
        "inclusion_criteria": "All Individuals:\n\n* Have been previously diagnosed with MM based on the International Myeloma Working Group (IMWG) 2016 criteria and currently requires treatment.\n* Must have measurable disease as defined by 1 or more of the following:\n\n  * Serum monoclonal protein (M-protein) ≥ 0.5 grams per deciliter (g/dL) (greater than or equal to [≥] 5 grams per liter [g/L]).\n  * Urine M-protein ≥ 200 mg/24 hours (h).\n  * Serum free light chain (SFLC) assay: involved SFLC level ≥ 10 mg/dL (100 mg/L) with abnormal SFLC ratio.\n* Has provided informed consent.\n* Is willing and able to comply with clinic visits and procedure outlined in the study protocol.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.\n* Life expectancy ≥ 3 months.\n* Absolute neutrophil count (ANC) ≥ 1000 cells/uL (1.0 x 10^9/L); granulocyte colony-stimulating factor (G-CSF) is not permitted within 1 week of screening to meet eligibility criteria.\n* Platelet count ≥ 75,000 cells/uL (75 x 10^9/L); platelet transfusion is not permitted within 1 week of screening to meet eligibility criteria.\n* Hemoglobin ≥ 9 g/dL; prior to initial dose of study treatment. Note: Transfusions are allowed to meet hemoglobin eligibility\n* Adequate liver function as demonstrated by the following:\n\n  * Aspartate aminotransferase (AST) ≤ 3.0 x upper limit of normal (ULN).\n  * Alanine aminotransferase (ALT) ≤ 3.0 x ULN.\n  * Total bilirubin ≤ 1.5 x ULN (or ≤ 3.0 x ULN and primarily unconjugated if individual has a documented history of Gilbert's syndrome or genetic equivalent).\n* International normalized ratio (INR) ≤ 1.2; Individuals receiving anticoagulation treatment may be allowed to participate if INR is within the therapeutic range prior to alternate assignment.\n* Individuals must have adequate renal function as demonstrated by a creatinine clearance ≥ 30 mL/min calculated by the Cockcroft-Gault formula or measured by 24 hours urine collection.\n* Corrected serum calcium ≤ 2.9 millimoles per liter (mmol/L) (11.5 mg/dL); measures to reduce calcium to acceptable levels, such as a short course of steroids, bisphosphonates, hydration, or calcitonin are acceptable.\n* Pretreatment blood cross-match completed.\n* Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.\n* Must be willing to consent to mandatory pretreatment and on-treatment bone marrow biopsies (trephines).\n* Magrolimab in Combination with Daratumumab: In addition to fulfilling the inclusion criteria for all individuals, individuals who are assigned to receive magrolimab in combination with daratumumab should fulfill the following:\n\n  * Must have received at least 3 previous lines of therapy for MM including an IMiD such as lenalidomide and a PI such as bortezomib.\n  * Individuals must have not had prior anti-cluster differentiation 38 (CD38) antibody therapy for at least 6 months prior to enrollment.\n  * No prior history of discontinuation of daratumumab due to toxicity.\n* Magrolimab in Combination with Pomalidomide and Dexamethasone: In addition to fulfilling the inclusion criteria for all Individuals, Individuals who are assigned to receive magrolimab in combination with pomalidomide and dexamethasone should fulfill the following:\n\n  * Must have received at least 3 previous lines of therapy for MM including an IMiD such as lenalidomide and a PI such as bortezomib.\n  * Prior treatment with pomalidomide is allowed if the Individual achieved at least a partial response (PR) to the most recent pomalidomide therapy and will have had at least a 6-month treatment-free interval from the last dose of pomalidomide until first study treatment.\n  * No prior history of discontinuation of pomalidomide due to toxicity.\n  * No contraindication to dexamethasone.\n* Magrolimab in Combination with Carfilzomib and Dexamethasone: In addition to fulfilling the inclusion criteria for all patients, patients who are assigned to receive magrolimab in combination with carfilzomib and dexamethasone should fulfill the following:\n\n  * Patient must have received at least 3 previous lines of therapy for MM including an IMiD such as lenalidomide and a PI such as bortezomib.\n  * Prior treatment with a PI, including carfilzomib, is allowed if the patient achieved at least a PR to the most recent prior PI therapy, and will have had at least a 6-month PI treatment-free interval from the last dose until first study treatment.\n  * No prior history of discontinuation of carfilzomib due to toxicity.\n  * No contraindication to dexamethasone\n* Magrolimab in Combination with Bortezomib and Dexamethasone: In addition to fulfilling the inclusion criteria for all individuals, individuals who are assigned to receive magrolimab in combination with bortezomib and dexamethasone should fulfill the following:\n\n  * Must have received at least 1 previous line of therapy for MM including an IMiD such as lenalidomide and a PI such as bortezomib.\n  * Prior treatment with a PI, including bortezomib, is allowed if the Individual achieved at least a PR to the most recent prior PI therapy, and will have had at least a 6-month PI treatment-free interval from the last dose until first study treatment.\n  * No prior history of discontinuation of bortezomib due to toxicity.\n  * No contraindication to dexamethasone.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Individuals with known amyloidosis including myeloma complicated by amyloidosis.\n* Multiple myeloma of immunoglobulin M subtype.\n* Individuals with Waldenstrom's macroglobulinemia.\n* Individuals with myelodysplastic syndrome (MDS).\n* Plasma cell leukemia (defined as either 20% of peripheral blood white blood cell (WBC) count comprised of plasma/CD138-positive cells) or circulating plasma cells ≥ 2 x 10^9/L.\n* Individuals with solitary bone or extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia.\n* Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes (POEMS) syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes).\n* Glucocorticoid therapy (prednisone > 40 mg/day or equivalent) within 14 days prior to enrollment; corticosteroid therapy for hypercalcemia is allowed.\n* Chemotherapy with approved or investigational anticancer therapeutics within 28 days prior to enrollment.\n* Focal radiation therapy within 7 days prior to enrollment; radiation therapy to an extended field involving a significant volume of bone marrow within 21 days prior to enrollment (ie, prior radiation must have been to less than 30% of the bone marrow).\n* Immunotherapy within 28 days prior to enrollment.\n* Major surgery (excluding procedures to stabilize the vertebrae) within 28 days prior to enrollment.\n* Positive serum pregnancy test.\n* Breastfeeding female.\n* Known hypersensitivity to any of the study drugs, the metabolites, or formulation excipient.\n* Prior treatment with CD47 or signal regulatory protein alpha (SIRPα)-targeting agents.\n* Current participation in another interventional clinical trial.\n* Autologous stem cell transplant < 100 days prior to enrollment.\n* Considered eligible to receive autologous or allogeneic stem cell transplant (SCT) at the time of enrollment.\n* Allogeneic SCT for the treatment of MM within 6 months of enrollment or active graft-versus-host disease requiring immunosuppression.\n* Significant neuropathy (Grade 3 to 4, or Grade 2 with pain) within 14 days prior to enrollment.\n* Known inherited or acquired bleeding disorders.\n* Known cirrhosis.\n* Clinical suspicion or documentation of central nervous system (CNS) disease.\n* Significant disease or medical conditions, as assessed by the investigator and sponsor, that would substantially increase the risk-benefit ratio of participating in the study. This includes, but is not limited to, acute myocardial infarction within the last 6 months, unstable angina, uncontrolled diabetes mellitus, significant active infections, congestive heart failure, or New York Heart Association (NYHA) Class III or IV heart failure.\n* Acute active infection requiring systemic antibiotics, antiviral (except antiviral therapy directed against reactivation) or antifungal agents within 14 days prior to enrollment.\n* Second malignancy, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, or other malignancies for which patients are not on active anticancer therapies and have had no evidence of active malignancy for at least 1 year. Other exceptions may be considered with sponsor approval. Previous hormonal therapy with luteinizing hormone-releasing hormone agonists for prostate cancer and treatment with bisphosphonates and receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors are not criteria for exclusion.\n* Known active or chronic hepatitis B or C infection or human immunodeficiency virus (HIV) infection in medical history.\n* Active hepatitis B virus (HBV) and/or active hepatitis C virus (HCV), and/or HIV infection following testing at screening:\n* Individuals who test positive for hepatitis B surface antigen (HBsAg). Patients who test positive for hepatitis B core antibody (anti-HBc) will require HBV DNA by quantitative polymerase chain reaction (PCR) for confirmation of active disease.\n* Individuals who test positive for HCV antibody. Patients who test positive for HCV antibody will require HCV ribonucleic acid (RNA) by quantitative PCR for confirmation of active disease.\n* Individuals who test positive for HIV.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
        "miscellaneous_criteria": "Key"
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "* Magrolimab in Combination with Daratumumab: In addition to fulfilling the inclusion criteria for all individuals, individuals who are assigned to receive magrolimab in combination with daratumumab should fulfill the following:",
                "criterions": [
                    {
                        "exact_snippets": "individuals who are assigned to receive magrolimab in combination with daratumumab should fulfill the following",
                        "criterion": "assignment to magrolimab and daratumumab combination",
                        "requirement": {
                            "requirement_type": "assignment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "individuals who are assigned to receive magrolimab in combination with daratumumab should fulfill the following",
                        "criterion": "assignment to magrolimab and daratumumab combination",
                        "requirement": {
                            "requirement_type": "assignment",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* No contraindication to dexamethasone.",
                "criterions": [
                    {
                        "exact_snippets": "No contraindication to dexamethasone",
                        "criterion": "contraindication to dexamethasone",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "No contraindication to dexamethasone",
                        "criterion": "contraindication to dexamethasone",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Life expectancy ≥ 3 months.",
                "criterions": [
                    {
                        "exact_snippets": "Life expectancy ≥ 3 months",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Life expectancy ≥ 3 months",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Pretreatment blood cross-match completed.",
                "criterions": [
                    {
                        "exact_snippets": "Pretreatment blood cross-match completed",
                        "criterion": "blood cross-match",
                        "requirement": {
                            "requirement_type": "completion",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Pretreatment blood cross-match completed",
                        "criterion": "blood cross-match",
                        "requirement": {
                            "requirement_type": "completion",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Corrected serum calcium ≤ 2.9 millimoles per liter (mmol/L) (11.5 mg/dL); measures to reduce calcium to acceptable levels, such as a short course of steroids, bisphosphonates, hydration, or calcitonin are acceptable.",
                "criterions": [
                    {
                        "exact_snippets": "Corrected serum calcium ≤ 2.9 millimoles per liter (mmol/L) (11.5 mg/dL)",
                        "criterion": "corrected serum calcium",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.9,
                                "unit": "mmol/L"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Corrected serum calcium ≤ 2.9 millimoles per liter (mmol/L) (11.5 mg/dL)",
                        "criterion": "corrected serum calcium",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 11.5,
                                "unit": "mg/dL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Corrected serum calcium ≤ 2.9 millimoles per liter (mmol/L) (11.5 mg/dL)",
                        "criterion": "corrected serum calcium",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.9,
                                "unit": "mmol/L"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Corrected serum calcium ≤ 2.9 millimoles per liter (mmol/L) (11.5 mg/dL)",
                        "criterion": "corrected serum calcium",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 11.5,
                                "unit": "mg/dL"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Must have measurable disease as defined by 1 or more of the following:",
                "criterions": [
                    {
                        "exact_snippets": "Must have measurable disease",
                        "criterion": "measurable disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Must have measurable disease",
                        "criterion": "measurable disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Have been previously diagnosed with MM based on the International Myeloma Working Group (IMWG) 2016 criteria and currently requires treatment.",
                "criterions": [
                    {
                        "exact_snippets": "previously diagnosed with MM based on the International Myeloma Working Group (IMWG) 2016 criteria",
                        "criterion": "multiple myeloma diagnosis",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "previously diagnosed with MM based on the International Myeloma Working Group (IMWG) 2016 criteria",
                        "criterion": "multiple myeloma diagnosis",
                        "requirement": {
                            "requirement_type": "diagnostic_criteria",
                            "expected_value": "International Myeloma Working Group (IMWG) 2016 criteria"
                        }
                    },
                    {
                        "exact_snippets": "currently requires treatment",
                        "criterion": "requirement for treatment",
                        "requirement": {
                            "requirement_type": "treatment necessity",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "previously diagnosed with MM based on the International Myeloma Working Group (IMWG) 2016 criteria",
                        "criterion": "multiple myeloma diagnosis",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "previously diagnosed with MM based on the International Myeloma Working Group (IMWG) 2016 criteria",
                        "criterion": "multiple myeloma diagnosis",
                        "requirement": {
                            "requirement_type": "diagnostic_criteria",
                            "expected_value": "International Myeloma Working Group (IMWG) 2016 criteria"
                        }
                    },
                    {
                        "exact_snippets": "currently requires treatment",
                        "criterion": "requirement for treatment",
                        "requirement": {
                            "requirement_type": "treatment necessity",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Individuals must have not had prior anti-cluster differentiation 38 (CD38) antibody therapy for at least 6 months prior to enrollment.",
                "criterions": [
                    {
                        "exact_snippets": "not had prior anti-cluster differentiation 38 (CD38) antibody therapy for at least 6 months prior to enrollment",
                        "criterion": "prior anti-CD38 antibody therapy",
                        "requirement": {
                            "requirement_type": "absence duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "not had prior anti-cluster differentiation 38 (CD38) antibody therapy for at least 6 months prior to enrollment",
                        "criterion": "prior anti-CD38 antibody therapy",
                        "requirement": {
                            "requirement_type": "absence duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "All Individuals:",
                "criterions": [
                    {
                        "exact_snippets": "All Individuals",
                        "criterion": "individual",
                        "requirement": {
                            "requirement_type": "inclusion",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "All Individuals",
                        "criterion": "individual",
                        "requirement": {
                            "requirement_type": "inclusion",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Has provided informed consent.",
                "criterions": [
                    {
                        "exact_snippets": "Has provided informed consent",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Has provided informed consent",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Is willing and able to comply with clinic visits and procedure outlined in the study protocol.",
                "criterions": [
                    {
                        "exact_snippets": "Is willing and able to comply with clinic visits and procedure outlined in the study protocol.",
                        "criterion": "compliance with clinic visits and study procedures",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Is willing and able to comply with clinic visits and procedure outlined in the study protocol.",
                        "criterion": "compliance with clinic visits and study procedures",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Is willing and able to comply with clinic visits and procedure outlined in the study protocol.",
                        "criterion": "compliance with clinic visits and study procedures",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Is willing and able to comply with clinic visits and procedure outlined in the study protocol.",
                        "criterion": "compliance with clinic visits and study procedures",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Must have received at least 1 previous line of therapy for MM including an IMiD such as lenalidomide and a PI such as bortezomib.",
                "criterions": [
                    {
                        "exact_snippets": "Must have received at least 1 previous line of therapy for MM",
                        "criterion": "previous lines of therapy for multiple myeloma (MM)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    },
                    {
                        "exact_snippets": "including an IMiD such as lenalidomide",
                        "criterion": "prior exposure to IMiD",
                        "requirement": {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "and a PI such as bortezomib",
                        "criterion": "prior exposure to PI",
                        "requirement": {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Must have received at least 1 previous line of therapy for MM",
                        "criterion": "previous lines of therapy for multiple myeloma (MM)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    },
                    {
                        "exact_snippets": "including an IMiD such as lenalidomide",
                        "criterion": "prior exposure to IMiD",
                        "requirement": {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "and a PI such as bortezomib",
                        "criterion": "prior exposure to PI",
                        "requirement": {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patient must have received at least 3 previous lines of therapy for MM including an IMiD such as lenalidomide and a PI such as bortezomib.",
                "criterions": [
                    {
                        "exact_snippets": "received at least 3 previous lines of therapy for MM",
                        "criterion": "previous lines of therapy for multiple myeloma (MM)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "lines"
                            }
                        }
                    },
                    {
                        "exact_snippets": "including an IMiD such as lenalidomide",
                        "criterion": "prior therapy with IMiD",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "and a PI such as bortezomib",
                        "criterion": "prior therapy with PI",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "received at least 3 previous lines of therapy for MM",
                        "criterion": "previous lines of therapy for multiple myeloma (MM)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "lines"
                            }
                        }
                    },
                    {
                        "exact_snippets": "including an IMiD such as lenalidomide",
                        "criterion": "prior therapy with IMiD",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "and a PI such as bortezomib",
                        "criterion": "prior therapy with PI",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Adequate liver function as demonstrated by the following:",
                "criterions": [
                    {
                        "exact_snippets": "Adequate liver function",
                        "criterion": "liver function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Adequate liver function",
                        "criterion": "liver function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* No prior history of discontinuation of bortezomib due to toxicity.",
                "criterions": [
                    {
                        "exact_snippets": "No prior history of discontinuation of bortezomib due to toxicity",
                        "criterion": "discontinuation of bortezomib due to toxicity",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "No prior history of discontinuation of bortezomib due to toxicity",
                        "criterion": "discontinuation of bortezomib due to toxicity",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* No prior history of discontinuation of daratumumab due to toxicity.",
                "criterions": [
                    {
                        "exact_snippets": "No prior history of discontinuation of daratumumab due to toxicity",
                        "criterion": "daratumumab discontinuation due to toxicity",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "No prior history of discontinuation of daratumumab due to toxicity",
                        "criterion": "daratumumab discontinuation due to toxicity",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* No prior history of discontinuation of carfilzomib due to toxicity.",
                "criterions": [
                    {
                        "exact_snippets": "No prior history of discontinuation of carfilzomib due to toxicity",
                        "criterion": "discontinuation of carfilzomib due to toxicity",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "No prior history of discontinuation of carfilzomib due to toxicity",
                        "criterion": "discontinuation of carfilzomib due to toxicity",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Key",
                "criterions": [
                    {
                        "exact_snippets": "Key",
                        "criterion": "key eligibility criteria",
                        "requirement": {
                            "requirement_type": "N/A",
                            "expected_value": "N/A"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Key",
                        "criterion": "key eligibility criteria",
                        "requirement": {
                            "requirement_type": "N/A",
                            "expected_value": "N/A"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* No contraindication to dexamethasone.",
                "criterions": [
                    {
                        "exact_snippets": "No contraindication to dexamethasone",
                        "criterion": "contraindication to dexamethasone",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "No contraindication to dexamethasone",
                        "criterion": "contraindication to dexamethasone",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* No prior history of discontinuation of pomalidomide due to toxicity.",
                "criterions": [
                    {
                        "exact_snippets": "No prior history of discontinuation of pomalidomide due to toxicity",
                        "criterion": "history of discontinuation of pomalidomide due to toxicity",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "No prior history of discontinuation of pomalidomide due to toxicity",
                        "criterion": "history of discontinuation of pomalidomide due to toxicity",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.",
                "criterions": [
                    {
                        "exact_snippets": "Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.",
                        "criterion": "childbearing potential",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "who engage in heterosexual intercourse",
                        "criterion": "engagement in heterosexual intercourse",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must agree to use protocol-specified method(s) of contraception",
                        "criterion": "use of protocol-specified contraception",
                        "requirement": {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "and_criteria": [
                        {
                            "exact_snippets": "Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.",
                            "criterion": "childbearing potential",
                            "requirement": {
                                "requirement_type": "status",
                                "expected_value": true
                            }
                        },
                        {
                            "exact_snippets": "who engage in heterosexual intercourse",
                            "criterion": "engagement in heterosexual intercourse",
                            "requirement": {
                                "requirement_type": "status",
                                "expected_value": true
                            }
                        }
                    ]
                },
                "then_criteria": {
                    "exact_snippets": "must agree to use protocol-specified method(s) of contraception",
                    "criterion": "use of protocol-specified contraception",
                    "requirement": {
                        "requirement_type": "agreement to use",
                        "expected_value": true
                    }
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "* Must have received at least 3 previous lines of therapy for MM including an IMiD such as lenalidomide and a PI such as bortezomib.",
                "criterions": [
                    {
                        "exact_snippets": "Must have received at least 3 previous lines of therapy for MM",
                        "criterion": "previous lines of therapy for multiple myeloma (MM)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "lines"
                            }
                        }
                    },
                    {
                        "exact_snippets": "including an IMiD such as lenalidomide",
                        "criterion": "prior therapy with IMiD",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "and a PI such as bortezomib",
                        "criterion": "prior therapy with PI",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Must have received at least 3 previous lines of therapy for MM",
                        "criterion": "previous lines of therapy for multiple myeloma (MM)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "lines"
                            }
                        }
                    },
                    {
                        "exact_snippets": "including an IMiD such as lenalidomide",
                        "criterion": "prior therapy with IMiD",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "and a PI such as bortezomib",
                        "criterion": "prior therapy with PI",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Alanine aminotransferase (ALT) ≤ 3.0 x ULN.",
                "criterions": [
                    {
                        "exact_snippets": "Alanine aminotransferase (ALT) ≤ 3.0 x ULN",
                        "criterion": "alanine aminotransferase (ALT) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Alanine aminotransferase (ALT) ≤ 3.0 x ULN",
                        "criterion": "alanine aminotransferase (ALT) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Prior treatment with a PI, including bortezomib, is allowed if the Individual achieved at least a PR to the most recent prior PI therapy, and will have had at least a 6-month PI treatment-free interval from the last dose until first study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Prior treatment with a PI, including bortezomib, is allowed",
                        "criterion": "prior treatment with a PI",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "achieved at least a PR to the most recent prior PI therapy",
                        "criterion": "response to most recent prior PI therapy",
                        "requirement": {
                            "requirement_type": "response",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "PR"
                            }
                        }
                    },
                    {
                        "exact_snippets": "at least a 6-month PI treatment-free interval from the last dose until first study treatment",
                        "criterion": "PI treatment-free interval",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "month"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "condition": {
                            "exact_snippets": "Prior treatment with a PI, including bortezomib, is allowed",
                            "criterion": "prior treatment with a PI",
                            "requirement": {
                                "requirement_type": "history of treatment",
                                "expected_value": true
                            }
                        },
                        "then_criteria": {
                            "and_criteria": [
                                {
                                    "exact_snippets": "achieved at least a PR to the most recent prior PI therapy",
                                    "criterion": "response to most recent prior PI therapy",
                                    "requirement": {
                                        "requirement_type": "response",
                                        "expected_value": {
                                            "operator": ">=",
                                            "value": 1,
                                            "unit": "PR"
                                        }
                                    }
                                },
                                {
                                    "exact_snippets": "at least a 6-month PI treatment-free interval from the last dose until first study treatment",
                                    "criterion": "PI treatment-free interval",
                                    "requirement": {
                                        "requirement_type": "duration",
                                        "expected_value": {
                                            "operator": ">=",
                                            "value": 6,
                                            "unit": "month"
                                        }
                                    }
                                }
                            ]
                        },
                        "else_criteria": null
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* No contraindication to dexamethasone",
                "criterions": [
                    {
                        "exact_snippets": "No contraindication to dexamethasone",
                        "criterion": "contraindication to dexamethasone",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "No contraindication to dexamethasone",
                        "criterion": "contraindication to dexamethasone",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Aspartate aminotransferase (AST) ≤ 3.0 x upper limit of normal (ULN).",
                "criterions": [
                    {
                        "exact_snippets": "Aspartate aminotransferase (AST) ≤ 3.0 x upper limit of normal (ULN)",
                        "criterion": "aspartate aminotransferase (AST) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Aspartate aminotransferase (AST) ≤ 3.0 x upper limit of normal (ULN)",
                        "criterion": "aspartate aminotransferase (AST) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Must have received at least 3 previous lines of therapy for MM including an IMiD such as lenalidomide and a PI such as bortezomib.",
                "criterions": [
                    {
                        "exact_snippets": "Must have received at least 3 previous lines of therapy for MM",
                        "criterion": "previous lines of therapy for multiple myeloma (MM)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "lines"
                            }
                        }
                    },
                    {
                        "exact_snippets": "including an IMiD such as lenalidomide",
                        "criterion": "prior therapy with IMiD",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "a PI such as bortezomib",
                        "criterion": "prior therapy with PI",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Must have received at least 3 previous lines of therapy for MM",
                        "criterion": "previous lines of therapy for multiple myeloma (MM)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "lines"
                            }
                        }
                    },
                    {
                        "exact_snippets": "including an IMiD such as lenalidomide",
                        "criterion": "prior therapy with IMiD",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "a PI such as bortezomib",
                        "criterion": "prior therapy with PI",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Prior treatment with pomalidomide is allowed if the Individual achieved at least a partial response (PR) to the most recent pomalidomide therapy and will have had at least a 6-month treatment-free interval from the last dose of pomalidomide until first study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Prior treatment with pomalidomide is allowed if the Individual achieved at least a partial response (PR) to the most recent pomalidomide therapy",
                        "criterion": "response to most recent pomalidomide therapy",
                        "requirement": {
                            "requirement_type": "response",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0,
                                "unit": "PR"
                            }
                        }
                    },
                    {
                        "exact_snippets": "will have had at least a 6-month treatment-free interval from the last dose of pomalidomide until first study treatment",
                        "criterion": "treatment-free interval from last dose of pomalidomide",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "month"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "and_criteria": [
                        {
                            "exact_snippets": "Prior treatment with pomalidomide is allowed if the Individual achieved at least a partial response (PR) to the most recent pomalidomide therapy",
                            "criterion": "response to most recent pomalidomide therapy",
                            "requirement": {
                                "requirement_type": "response",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 0,
                                    "unit": "PR"
                                }
                            }
                        },
                        {
                            "exact_snippets": "will have had at least a 6-month treatment-free interval from the last dose of pomalidomide until first study treatment",
                            "criterion": "treatment-free interval from last dose of pomalidomide",
                            "requirement": {
                                "requirement_type": "duration",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 6,
                                    "unit": "month"
                                }
                            }
                        }
                    ]
                },
                "then_criteria": null,
                "else_criteria": null
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "* Breastfeeding female.",
                "criterions": [
                    {
                        "exact_snippets": "Breastfeeding female",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "breastfeeding"
                        }
                    },
                    {
                        "exact_snippets": "Breastfeeding female",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Breastfeeding female",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "breastfeeding"
                        }
                    },
                    {
                        "exact_snippets": "Breastfeeding female",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Plasma cell leukemia (defined as either 20% of peripheral blood white blood cell (WBC) count comprised of plasma/CD138-positive cells) or circulating plasma cells ≥ 2 x 10^9/L.",
                "criterions": [
                    {
                        "exact_snippets": "Plasma cell leukemia (defined as either 20% of peripheral blood white blood cell (WBC) count comprised of plasma/CD138-positive cells)",
                        "criterion": "plasma cell leukemia",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Plasma cell leukemia (defined as either 20% of peripheral blood white blood cell (WBC) count comprised of plasma/CD138-positive cells)",
                        "criterion": "plasma cell leukemia",
                        "requirement": {
                            "requirement_type": "definition",
                            "expected_value": "20% of peripheral blood white blood cell (WBC) count comprised of plasma/CD138-positive cells"
                        }
                    },
                    {
                        "exact_snippets": "circulating plasma cells ≥ 2 x 10^9/L",
                        "criterion": "circulating plasma cells",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2000000000.0,
                                "unit": "cells/L"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Plasma cell leukemia (defined as either 20% of peripheral blood white blood cell (WBC) count comprised of plasma/CD138-positive cells)",
                                "criterion": "plasma cell leukemia",
                                "requirement": {
                                    "requirement_type": "diagnosis",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Plasma cell leukemia (defined as either 20% of peripheral blood white blood cell (WBC) count comprised of plasma/CD138-positive cells)",
                                "criterion": "plasma cell leukemia",
                                "requirement": {
                                    "requirement_type": "definition",
                                    "expected_value": "20% of peripheral blood white blood cell (WBC) count comprised of plasma/CD138-positive cells"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "circulating plasma cells ≥ 2 x 10^9/L",
                        "criterion": "circulating plasma cells",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2000000000.0,
                                "unit": "cells/L"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Major surgery (excluding procedures to stabilize the vertebrae) within 28 days prior to enrollment.",
                "criterions": [
                    {
                        "exact_snippets": "Major surgery (excluding procedures to stabilize the vertebrae) within 28 days prior to enrollment.",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Major surgery (excluding procedures to stabilize the vertebrae) within 28 days prior to enrollment.",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "exclusion",
                            "expected_value": "procedures to stabilize the vertebrae"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Major surgery (excluding procedures to stabilize the vertebrae) within 28 days prior to enrollment.",
                                "criterion": "major surgery",
                                "requirement": {
                                    "requirement_type": "recency",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 28,
                                        "unit": "days"
                                    }
                                }
                            },
                            {
                                "not_criteria": {
                                    "exact_snippets": "Major surgery (excluding procedures to stabilize the vertebrae) within 28 days prior to enrollment.",
                                    "criterion": "major surgery",
                                    "requirement": {
                                        "requirement_type": "exclusion",
                                        "expected_value": "procedures to stabilize the vertebrae"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Allogeneic SCT for the treatment of MM within 6 months of enrollment or active graft-versus-host disease requiring immunosuppression.",
                "criterions": [
                    {
                        "exact_snippets": "Allogeneic SCT for the treatment of MM within 6 months of enrollment",
                        "criterion": "allogeneic stem cell transplant for multiple myeloma",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Allogeneic SCT for the treatment of MM within 6 months of enrollment",
                        "criterion": "allogeneic stem cell transplant for multiple myeloma",
                        "requirement": {
                            "requirement_type": "procedure",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active graft-versus-host disease requiring immunosuppression",
                        "criterion": "active graft-versus-host disease",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "active graft-versus-host disease requiring immunosuppression",
                        "criterion": "active graft-versus-host disease",
                        "requirement": {
                            "requirement_type": "requiring immunosuppression",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Allogeneic SCT for the treatment of MM within 6 months of enrollment",
                                "criterion": "allogeneic stem cell transplant for multiple myeloma",
                                "requirement": {
                                    "requirement_type": "procedure",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Allogeneic SCT for the treatment of MM within 6 months of enrollment",
                                "criterion": "allogeneic stem cell transplant for multiple myeloma",
                                "requirement": {
                                    "requirement_type": "time since procedure",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "active graft-versus-host disease requiring immunosuppression",
                                "criterion": "active graft-versus-host disease",
                                "requirement": {
                                    "requirement_type": "activity",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "active graft-versus-host disease requiring immunosuppression",
                                "criterion": "active graft-versus-host disease",
                                "requirement": {
                                    "requirement_type": "requiring immunosuppression",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Current participation in another interventional clinical trial.",
                "criterions": [
                    {
                        "exact_snippets": "Current participation in another interventional clinical trial.",
                        "criterion": "participation in another interventional clinical trial",
                        "requirement": {
                            "requirement_type": "current status",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Current participation in another interventional clinical trial.",
                    "criterion": "participation in another interventional clinical trial",
                    "requirement": {
                        "requirement_type": "current status",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Individuals with known amyloidosis including myeloma complicated by amyloidosis.",
                "criterions": [
                    {
                        "exact_snippets": "known amyloidosis",
                        "criterion": "amyloidosis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "myeloma complicated by amyloidosis",
                        "criterion": "myeloma complicated by amyloidosis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "known amyloidosis",
                        "criterion": "amyloidosis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "myeloma complicated by amyloidosis",
                        "criterion": "myeloma complicated by amyloidosis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Known hypersensitivity to any of the study drugs, the metabolites, or formulation excipient.",
                "criterions": [
                    {
                        "exact_snippets": "Known hypersensitivity to any of the study drugs",
                        "criterion": "hypersensitivity to study drugs",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known hypersensitivity to ... the metabolites",
                        "criterion": "hypersensitivity to metabolites of study drugs",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known hypersensitivity to ... formulation excipient",
                        "criterion": "hypersensitivity to formulation excipient",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Known hypersensitivity to any of the study drugs",
                        "criterion": "hypersensitivity to study drugs",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known hypersensitivity to ... the metabolites",
                        "criterion": "hypersensitivity to metabolites of study drugs",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known hypersensitivity to ... formulation excipient",
                        "criterion": "hypersensitivity to formulation excipient",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Active hepatitis B virus (HBV) and/or active hepatitis C virus (HCV), and/or HIV infection following testing at screening:",
                "criterions": [
                    {
                        "exact_snippets": "Active hepatitis B virus (HBV) ... following testing at screening",
                        "criterion": "hepatitis B virus (HBV) infection",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Active hepatitis B virus (HBV) ... following testing at screening",
                        "criterion": "hepatitis B virus (HBV) infection",
                        "requirement": {
                            "requirement_type": "detection at screening",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Active ... hepatitis C virus (HCV) ... following testing at screening",
                        "criterion": "hepatitis C virus (HCV) infection",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Active ... hepatitis C virus (HCV) ... following testing at screening",
                        "criterion": "hepatitis C virus (HCV) infection",
                        "requirement": {
                            "requirement_type": "detection at screening",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "HIV infection following testing at screening",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "detection at screening",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Active hepatitis B virus (HBV) ... following testing at screening",
                                "criterion": "hepatitis B virus (HBV) infection",
                                "requirement": {
                                    "requirement_type": "activity",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Active hepatitis B virus (HBV) ... following testing at screening",
                                "criterion": "hepatitis B virus (HBV) infection",
                                "requirement": {
                                    "requirement_type": "detection at screening",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Active ... hepatitis C virus (HCV) ... following testing at screening",
                                "criterion": "hepatitis C virus (HCV) infection",
                                "requirement": {
                                    "requirement_type": "activity",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Active ... hepatitis C virus (HCV) ... following testing at screening",
                                "criterion": "hepatitis C virus (HCV) infection",
                                "requirement": {
                                    "requirement_type": "detection at screening",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "HIV infection following testing at screening",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "detection at screening",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Chemotherapy with approved or investigational anticancer therapeutics within 28 days prior to enrollment.",
                "criterions": [
                    {
                        "exact_snippets": "Chemotherapy with approved or investigational anticancer therapeutics within 28 days prior to enrollment.",
                        "criterion": "chemotherapy with approved or investigational anticancer therapeutics",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to enrollment"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Chemotherapy with approved or investigational anticancer therapeutics within 28 days prior to enrollment.",
                        "criterion": "chemotherapy with approved or investigational anticancer therapeutics",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to enrollment"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Individuals with Waldenstrom's macroglobulinemia.",
                "criterions": [
                    {
                        "exact_snippets": "Individuals with Waldenstrom's macroglobulinemia",
                        "criterion": "Waldenstrom's macroglobulinemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Individuals with Waldenstrom's macroglobulinemia",
                    "criterion": "Waldenstrom's macroglobulinemia",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Multiple myeloma of immunoglobulin M subtype.",
                "criterions": [
                    {
                        "exact_snippets": "Multiple myeloma of immunoglobulin M subtype",
                        "criterion": "multiple myeloma",
                        "requirement": {
                            "requirement_type": "subtype",
                            "expected_value": "immunoglobulin M"
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Multiple myeloma of immunoglobulin M subtype",
                    "criterion": "multiple myeloma",
                    "requirement": {
                        "requirement_type": "subtype",
                        "expected_value": "immunoglobulin M"
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes (POEMS) syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes).",
                "criterions": [
                    {
                        "exact_snippets": "Polyneuropathy",
                        "criterion": "polyneuropathy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Organomegaly",
                        "criterion": "organomegaly",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Endocrinopathy",
                        "criterion": "endocrinopathy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Monoclonal protein",
                        "criterion": "monoclonal protein (M-protein)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Skin changes",
                        "criterion": "skin changes",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Polyneuropathy",
                        "criterion": "polyneuropathy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Organomegaly",
                        "criterion": "organomegaly",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Endocrinopathy",
                        "criterion": "endocrinopathy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Monoclonal protein",
                        "criterion": "monoclonal protein (M-protein)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Skin changes",
                        "criterion": "skin changes",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Autologous stem cell transplant < 100 days prior to enrollment.",
                "criterions": [
                    {
                        "exact_snippets": "Autologous stem cell transplant < 100 days prior to enrollment.",
                        "criterion": "autologous stem cell transplant",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<",
                                "value": 100,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Autologous stem cell transplant < 100 days prior to enrollment.",
                        "criterion": "autologous stem cell transplant",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<",
                                "value": 100,
                                "unit": "days"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Individuals who test positive for HIV.",
                "criterions": [
                    {
                        "exact_snippets": "Individuals who test positive for HIV",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Individuals who test positive for HIV",
                    "criterion": "HIV infection",
                    "requirement": {
                        "requirement_type": "test result",
                        "expected_value": "positive"
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Known cirrhosis.",
                "criterions": [
                    {
                        "exact_snippets": "Known cirrhosis.",
                        "criterion": "cirrhosis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known cirrhosis.",
                        "criterion": "cirrhosis",
                        "requirement": {
                            "requirement_type": "awareness/status",
                            "expected_value": "known"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Known cirrhosis.",
                        "criterion": "cirrhosis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known cirrhosis.",
                        "criterion": "cirrhosis",
                        "requirement": {
                            "requirement_type": "awareness/status",
                            "expected_value": "known"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Note: Other protocol defined Inclusion/Exclusion criteria may apply.",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "* Individuals with myelodysplastic syndrome (MDS).",
                "criterions": [
                    {
                        "exact_snippets": "Individuals with myelodysplastic syndrome (MDS)",
                        "criterion": "myelodysplastic syndrome (MDS)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Individuals with myelodysplastic syndrome (MDS)",
                    "criterion": "myelodysplastic syndrome (MDS)",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Positive serum pregnancy test.",
                "criterions": [
                    {
                        "exact_snippets": "Positive serum pregnancy test.",
                        "criterion": "serum pregnancy test",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Positive serum pregnancy test.",
                    "criterion": "serum pregnancy test",
                    "requirement": {
                        "requirement_type": "result",
                        "expected_value": "positive"
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Focal radiation therapy within 7 days prior to enrollment; radiation therapy to an extended field involving a significant volume of bone marrow within 21 days prior to enrollment (ie, prior radiation must have been to less than 30% of the bone marrow).",
                "criterions": [
                    {
                        "exact_snippets": "Focal radiation therapy within 7 days prior to enrollment",
                        "criterion": "focal radiation therapy",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "radiation therapy to an extended field involving a significant volume of bone marrow within 21 days prior to enrollment",
                        "criterion": "extended field radiation therapy involving significant bone marrow",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "prior radiation must have been to less than 30% of the bone marrow",
                        "criterion": "prior radiation to bone marrow",
                        "requirement": {
                            "requirement_type": "percentage of bone marrow irradiated",
                            "expected_value": {
                                "operator": "<",
                                "value": 30,
                                "unit": "%"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Focal radiation therapy within 7 days prior to enrollment",
                        "criterion": "focal radiation therapy",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "radiation therapy to an extended field involving a significant volume of bone marrow within 21 days prior to enrollment",
                                "criterion": "extended field radiation therapy involving significant bone marrow",
                                "requirement": {
                                    "requirement_type": "time since last treatment",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 21,
                                        "unit": "days"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "prior radiation must have been to less than 30% of the bone marrow",
                                "criterion": "prior radiation to bone marrow",
                                "requirement": {
                                    "requirement_type": "percentage of bone marrow irradiated",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 30,
                                        "unit": "%"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Individuals with solitary bone or extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia.",
                "criterions": [
                    {
                        "exact_snippets": "solitary bone or extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia",
                        "criterion": "solitary bone plasmacytoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "solitary bone or extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia",
                        "criterion": "solitary bone plasmacytoma",
                        "requirement": {
                            "requirement_type": "only evidence of plasma cell dyscrasia",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "solitary bone or extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia",
                        "criterion": "extramedullary plasmacytoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "solitary bone or extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia",
                        "criterion": "extramedullary plasmacytoma",
                        "requirement": {
                            "requirement_type": "only evidence of plasma cell dyscrasia",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "solitary bone or extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia",
                                "criterion": "solitary bone plasmacytoma",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "solitary bone or extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia",
                                "criterion": "solitary bone plasmacytoma",
                                "requirement": {
                                    "requirement_type": "only evidence of plasma cell dyscrasia",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "solitary bone or extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia",
                                "criterion": "extramedullary plasmacytoma",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "solitary bone or extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia",
                                "criterion": "extramedullary plasmacytoma",
                                "requirement": {
                                    "requirement_type": "only evidence of plasma cell dyscrasia",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Individuals who test positive for HCV antibody. Patients who test positive for HCV antibody will require HCV ribonucleic acid (RNA) by quantitative PCR for confirmation of active disease.",
                "criterions": [
                    {
                        "exact_snippets": "test positive for HCV antibody",
                        "criterion": "HCV antibody",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "HCV ribonucleic acid (RNA) by quantitative PCR for confirmation of active disease",
                        "criterion": "HCV RNA (by quantitative PCR)",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "confirmation of active disease"
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "test positive for HCV antibody",
                    "criterion": "HCV antibody",
                    "requirement": {
                        "requirement_type": "test result",
                        "expected_value": "positive"
                    }
                },
                "then_criteria": {
                    "exact_snippets": "HCV ribonucleic acid (RNA) by quantitative PCR for confirmation of active disease",
                    "criterion": "HCV RNA (by quantitative PCR)",
                    "requirement": {
                        "requirement_type": "test result",
                        "expected_value": "confirmation of active disease"
                    }
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "* Prior treatment with CD47 or signal regulatory protein alpha (SIRPα)-targeting agents.",
                "criterions": [
                    {
                        "exact_snippets": "Prior treatment with CD47 or signal regulatory protein alpha (SIRPα)-targeting agents.",
                        "criterion": "prior treatment with CD47-targeting agents",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment with ... signal regulatory protein alpha (SIRPα)-targeting agents.",
                        "criterion": "prior treatment with SIRPα-targeting agents",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Prior treatment with CD47 or signal regulatory protein alpha (SIRPα)-targeting agents.",
                        "criterion": "prior treatment with CD47-targeting agents",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Prior treatment with ... signal regulatory protein alpha (SIRPα)-targeting agents.",
                        "criterion": "prior treatment with SIRPα-targeting agents",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Individuals who test positive for hepatitis B surface antigen (HBsAg). Patients who test positive for hepatitis B core antibody (anti-HBc) will require HBV DNA by quantitative polymerase chain reaction (PCR) for confirmation of active disease.",
                "criterions": [
                    {
                        "exact_snippets": "test positive for hepatitis B surface antigen (HBsAg)",
                        "criterion": "hepatitis B surface antigen (HBsAg)",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "test positive for hepatitis B core antibody (anti-HBc) ... will require HBV DNA by quantitative polymerase chain reaction (PCR) for confirmation of active disease",
                        "criterion": "hepatitis B core antibody (anti-HBc)",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "HBV DNA by quantitative polymerase chain reaction (PCR) for confirmation of active disease",
                        "criterion": "HBV DNA (by quantitative PCR)",
                        "requirement": {
                            "requirement_type": "confirmation of active disease",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "test positive for hepatitis B surface antigen (HBsAg)",
                        "criterion": "hepatitis B surface antigen (HBsAg)",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "test positive for hepatitis B core antibody (anti-HBc) ... will require HBV DNA by quantitative polymerase chain reaction (PCR) for confirmation of active disease",
                                "criterion": "hepatitis B core antibody (anti-HBc)",
                                "requirement": {
                                    "requirement_type": "test result",
                                    "expected_value": "positive"
                                }
                            },
                            {
                                "exact_snippets": "HBV DNA by quantitative polymerase chain reaction (PCR) for confirmation of active disease",
                                "criterion": "HBV DNA (by quantitative PCR)",
                                "requirement": {
                                    "requirement_type": "confirmation of active disease",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Immunotherapy within 28 days prior to enrollment.",
                "criterions": [
                    {
                        "exact_snippets": "Immunotherapy within 28 days prior to enrollment.",
                        "criterion": "immunotherapy",
                        "requirement": {
                            "requirement_type": "exposure timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to enrollment"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Immunotherapy within 28 days prior to enrollment.",
                        "criterion": "immunotherapy",
                        "requirement": {
                            "requirement_type": "exposure timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to enrollment"
                            }
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [
        {
            "identified_line": {
                "line": "Key",
                "criterions": [
                    {
                        "exact_snippets": "Key",
                        "criterion": "key status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "key"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Key",
                        "criterion": "key status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "key"
                        }
                    }
                ]
            }
        }
    ],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* Magrolimab in Combination with Pomalidomide and Dexamethasone: In addition to fulfilling the inclusion criteria for all Individuals, Individuals who are assigned to receive magrolimab in combination with pomalidomide and dexamethasone should fulfill the following:",
                "criterions": [
                    {
                        "exact_snippets": "assigned to receive magrolimab in combination with pomalidomide and dexamethasone",
                        "criterion": "treatment assignment",
                        "requirement": {
                            "requirement_type": "assigned treatment",
                            "expected_value": [
                                "magrolimab",
                                "pomalidomide",
                                "dexamethasone"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "fulfilling the inclusion criteria for all Individuals",
                        "criterion": "general inclusion criteria",
                        "requirement": {
                            "requirement_type": "fulfillment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Total bilirubin ≤ 1.5 x ULN (or ≤ 3.0 x ULN and primarily unconjugated if individual has a documented history of Gilbert's syndrome or genetic equivalent).",
                "criterions": [
                    {
                        "exact_snippets": "Total bilirubin ≤ 1.5 x ULN",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Total bilirubin ... ≤ 3.0 x ULN and primarily unconjugated if individual has a documented history of Gilbert's syndrome or genetic equivalent",
                        "criterion": "total bilirubin in individuals with Gilbert's syndrome or genetic equivalent",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Total bilirubin ... ≤ 3.0 x ULN and primarily unconjugated if individual has a documented history of Gilbert's syndrome or genetic equivalent",
                        "criterion": "total bilirubin in individuals with Gilbert's syndrome or genetic equivalent",
                        "requirement": {
                            "requirement_type": "conjugation status",
                            "expected_value": "primarily unconjugated"
                        }
                    },
                    {
                        "exact_snippets": "documented history of Gilbert's syndrome or genetic equivalent",
                        "criterion": "history of Gilbert's syndrome or genetic equivalent",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Total bilirubin \u00103 1.5 x ULN",
                                "criterion": "total bilirubin",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "x ULN"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "documented history of Gilbert's syndrome or genetic equivalent",
                                "criterion": "history of Gilbert's syndrome or genetic equivalent",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Total bilirubin ... \u00103 3.0 x ULN and primarily unconjugated if individual has a documented history of Gilbert's syndrome or genetic equivalent",
                                "criterion": "total bilirubin in individuals with Gilbert's syndrome or genetic equivalent",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 3.0,
                                        "unit": "x ULN"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Total bilirubin ... \u00103 3.0 x ULN and primarily unconjugated if individual has a documented history of Gilbert's syndrome or genetic equivalent",
                                "criterion": "total bilirubin in individuals with Gilbert's syndrome or genetic equivalent",
                                "requirement": {
                                    "requirement_type": "conjugation status",
                                    "expected_value": "primarily unconjugated"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Absolute neutrophil count (ANC) ≥ 1000 cells/uL (1.0 x 10^9/L); granulocyte colony-stimulating factor (G-CSF) is not permitted within 1 week of screening to meet eligibility criteria.",
                "criterions": [
                    {
                        "exact_snippets": "Absolute neutrophil count (ANC) ≥ 1000 cells/uL (1.0 x 10^9/L)",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "cells/uL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Absolute neutrophil count (ANC) ≥ 1000 cells/uL (1.0 x 10^9/L)",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.0,
                                "unit": "x 10^9/L"
                            }
                        }
                    },
                    {
                        "exact_snippets": "granulocyte colony-stimulating factor (G-CSF) is not permitted within 1 week of screening to meet eligibility criteria",
                        "criterion": "granulocyte colony-stimulating factor (G-CSF) administration",
                        "requirement": {
                            "requirement_type": "administration within 1 week of screening",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Absolute neutrophil count (ANC) \u001e 1000 cells/uL (1.0 x 10^9/L)",
                                "criterion": "absolute neutrophil count (ANC)",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 1000,
                                        "unit": "cells/uL"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Absolute neutrophil count (ANC) \u001e 1000 cells/uL (1.0 x 10^9/L)",
                                "criterion": "absolute neutrophil count (ANC)",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 1.0,
                                        "unit": "x 10^9/L"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "granulocyte colony-stimulating factor (G-CSF) is not permitted within 1 week of screening to meet eligibility criteria",
                        "criterion": "granulocyte colony-stimulating factor (G-CSF) administration",
                        "requirement": {
                            "requirement_type": "administration within 1 week of screening",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Hemoglobin ≥ 9 g/dL; prior to initial dose of study treatment. Note: Transfusions are allowed to meet hemoglobin eligibility",
                "criterions": [
                    {
                        "exact_snippets": "Hemoglobin ≥ 9 g/dL",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Hemoglobin \u0013e 9 g/dL",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Urine M-protein ≥ 200 mg/24 hours (h).",
                "criterions": [
                    {
                        "exact_snippets": "Urine M-protein ≥ 200 mg/24 hours (h)",
                        "criterion": "urine M-protein",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 200,
                                "unit": "mg/24 hours"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Urine M-protein  200 mg/24 hours (h)",
                        "criterion": "urine M-protein",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 200,
                                "unit": "mg/24 hours"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Individuals must have adequate renal function as demonstrated by a creatinine clearance ≥ 30 mL/min calculated by the Cockcroft-Gault formula or measured by 24 hours urine collection.",
                "criterions": [
                    {
                        "exact_snippets": "adequate renal function as demonstrated by a creatinine clearance ≥ 30 mL/min",
                        "criterion": "renal function",
                        "requirement": {
                            "requirement_type": "creatinine clearance",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "calculated by the Cockcroft-Gault formula or measured by 24 hours urine collection",
                        "criterion": "creatinine clearance measurement method",
                        "requirement": {
                            "requirement_type": "measurement method",
                            "expected_value": [
                                "Cockcroft-Gault formula",
                                "24 hours urine collection"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* International normalized ratio (INR) ≤ 1.2; Individuals receiving anticoagulation treatment may be allowed to participate if INR is within the therapeutic range prior to alternate assignment.",
                "criterions": [
                    {
                        "exact_snippets": "International normalized ratio (INR) ≤ 1.2",
                        "criterion": "International normalized ratio (INR)",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.2,
                                "unit": ""
                            }
                        }
                    },
                    {
                        "exact_snippets": "Individuals receiving anticoagulation treatment ... if INR is within the therapeutic range prior to alternate assignment",
                        "criterion": "anticoagulation treatment and INR",
                        "requirement": {
                            "requirement_type": "anticoagulation treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Individuals receiving anticoagulation treatment ... if INR is within the therapeutic range prior to alternate assignment",
                        "criterion": "anticoagulation treatment and INR",
                        "requirement": {
                            "requirement_type": "INR therapeutic range",
                            "expected_value": "within therapeutic range prior to alternate assignment"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "International normalized ratio (INR) \u00104 1.2",
                                "criterion": "International normalized ratio (INR)",
                                "requirement": {
                                    "requirement_type": "value",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 1.2,
                                        "unit": ""
                                    }
                                }
                            },
                            {
                                "not_criteria": {
                                    "not_criteria": {
                                        "exact_snippets": "Individuals receiving anticoagulation treatment ... if INR is within the therapeutic range prior to alternate assignment",
                                        "criterion": "anticoagulation treatment and INR",
                                        "requirement": {
                                            "requirement_type": "anticoagulation treatment",
                                            "expected_value": true
                                        }
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Individuals receiving anticoagulation treatment ... if INR is within the therapeutic range prior to alternate assignment",
                                "criterion": "anticoagulation treatment and INR",
                                "requirement": {
                                    "requirement_type": "anticoagulation treatment",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Individuals receiving anticoagulation treatment ... if INR is within the therapeutic range prior to alternate assignment",
                                "criterion": "anticoagulation treatment and INR",
                                "requirement": {
                                    "requirement_type": "INR therapeutic range",
                                    "expected_value": "within therapeutic range prior to alternate assignment"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Prior treatment with a PI, including carfilzomib, is allowed if the patient achieved at least a PR to the most recent prior PI therapy, and will have had at least a 6-month PI treatment-free interval from the last dose until first study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Prior treatment with a PI, including carfilzomib, is allowed",
                        "criterion": "prior treatment with a PI",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "if the patient achieved at least a PR to the most recent prior PI therapy",
                        "criterion": "response to most recent prior PI therapy",
                        "requirement": {
                            "requirement_type": "response",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "PR"
                            }
                        }
                    },
                    {
                        "exact_snippets": "will have had at least a 6-month PI treatment-free interval from the last dose until first study treatment",
                        "criterion": "PI treatment-free interval",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "month"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "prior treatment with a PI, including carfilzomib, is allowed",
                        "criterion": "prior treatment with a PI",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "condition": {
                            "and_criteria": [
                                {
                                    "exact_snippets": "if the patient achieved at least a PR to the most recent prior PI therapy",
                                    "criterion": "response to most recent prior PI therapy",
                                    "requirement": {
                                        "requirement_type": "response",
                                        "expected_value": {
                                            "operator": ">=",
                                            "value": 1,
                                            "unit": "PR"
                                        }
                                    }
                                },
                                {
                                    "exact_snippets": "will have had at least a 6-month PI treatment-free interval from the last dose until first study treatment",
                                    "criterion": "PI treatment-free interval",
                                    "requirement": {
                                        "requirement_type": "duration",
                                        "expected_value": {
                                            "operator": ">=",
                                            "value": 6,
                                            "unit": "month"
                                        }
                                    }
                                }
                            ]
                        },
                        "then_criteria": null,
                        "else_criteria": null
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Platelet count ≥ 75,000 cells/uL (75 x 10^9/L); platelet transfusion is not permitted within 1 week of screening to meet eligibility criteria.",
                "criterions": [
                    {
                        "exact_snippets": "Platelet count ≥ 75,000 cells/uL (75 x 10^9/L)",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75000,
                                "unit": "cells/uL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "platelet transfusion is not permitted within 1 week of screening to meet eligibility criteria",
                        "criterion": "platelet transfusion within 1 week of screening",
                        "requirement": {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Platelet count \u001e 75,000 cells/uL (75 x 10^9/L)",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75000,
                                "unit": "cells/uL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "platelet transfusion is not permitted within 1 week of screening to meet eligibility criteria",
                        "criterion": "platelet transfusion within 1 week of screening",
                        "requirement": {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Serum free light chain (SFLC) assay: involved SFLC level ≥ 10 mg/dL (100 mg/L) with abnormal SFLC ratio.",
                "criterions": [
                    {
                        "exact_snippets": "involved SFLC level ≥ 10 mg/dL (100 mg/L)",
                        "criterion": "involved serum free light chain (SFLC) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "mg/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "involved SFLC level ≥ 10 mg/dL (100 mg/L)",
                        "criterion": "involved serum free light chain (SFLC) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "mg/L"
                            }
                        }
                    },
                    {
                        "exact_snippets": "abnormal SFLC ratio",
                        "criterion": "serum free light chain (SFLC) ratio",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "abnormal"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "involved SFLC level \u0010 10 mg/dL (100 mg/L)",
                                "criterion": "involved serum free light chain (SFLC) level",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 10,
                                        "unit": "mg/dL"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "involved SFLC level \u0010 10 mg/dL (100 mg/L)",
                                "criterion": "involved serum free light chain (SFLC) level",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 100,
                                        "unit": "mg/L"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "abnormal SFLC ratio",
                        "criterion": "serum free light chain (SFLC) ratio",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "abnormal"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Magrolimab in Combination with Bortezomib and Dexamethasone: In addition to fulfilling the inclusion criteria for all individuals, individuals who are assigned to receive magrolimab in combination with bortezomib and dexamethasone should fulfill the following:",
                "criterions": [
                    {
                        "exact_snippets": "fulfilling the inclusion criteria for all individuals",
                        "criterion": "general inclusion criteria",
                        "requirement": {
                            "requirement_type": "fulfillment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "assigned to receive magrolimab in combination with bortezomib and dexamethasone",
                        "criterion": "treatment assignment",
                        "requirement": {
                            "requirement_type": "assigned treatment",
                            "expected_value": [
                                "magrolimab",
                                "bortezomib",
                                "dexamethasone"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "should fulfill the following:",
                        "criterion": "additional criteria for combination therapy",
                        "requirement": {
                            "requirement_type": "fulfillment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Must be willing to consent to mandatory pretreatment and on-treatment bone marrow biopsies (trephines).",
                "criterions": [
                    {
                        "exact_snippets": "Must be willing to consent to mandatory pretreatment and on-treatment bone marrow biopsies (trephines)",
                        "criterion": "willingness to consent to bone marrow biopsies",
                        "requirement": {
                            "requirement_type": "willingness to consent",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Must be willing to consent to mandatory pretreatment and on-treatment bone marrow biopsies (trephines)",
                        "criterion": "willingness to consent to bone marrow biopsies",
                        "requirement": {
                            "requirement_type": "procedure type",
                            "expected_value": [
                                "pretreatment bone marrow biopsy",
                                "on-treatment bone marrow biopsy"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Must be willing to consent to mandatory pretreatment and on-treatment bone marrow biopsies (trephines)",
                        "criterion": "willingness to consent to bone marrow biopsies",
                        "requirement": {
                            "requirement_type": "procedure mandatory",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Serum monoclonal protein (M-protein) ≥ 0.5 grams per deciliter (g/dL) (greater than or equal to [≥] 5 grams per liter [g/L]).",
                "criterions": [
                    {
                        "exact_snippets": "Serum monoclonal protein (M-protein) ≥ 0.5 grams per deciliter (g/dL) (greater than or equal to [≥] 5 grams per liter [g/L])",
                        "criterion": "serum monoclonal protein (M-protein)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0.5,
                                        "unit": "g/dL"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "g/L"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Serum monoclonal protein (M-protein) \u001e 0.5 grams per deciliter (g/dL) (greater than or equal to [\u001e] 5 grams per liter [g/L])",
                        "criterion": "serum monoclonal protein (M-protein)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0.5,
                                        "unit": "g/dL"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "g/L"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Magrolimab in Combination with Carfilzomib and Dexamethasone: In addition to fulfilling the inclusion criteria for all patients, patients who are assigned to receive magrolimab in combination with carfilzomib and dexamethasone should fulfill the following:",
                "criterions": [
                    {
                        "exact_snippets": "fulfilling the inclusion criteria for all patients",
                        "criterion": "general inclusion criteria",
                        "requirement": {
                            "requirement_type": "fulfillment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "assigned to receive magrolimab in combination with carfilzomib and dexamethasone",
                        "criterion": "treatment assignment",
                        "requirement": {
                            "requirement_type": "assigned treatment",
                            "expected_value": [
                                "magrolimab",
                                "carfilzomib",
                                "dexamethasone"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "* Clinical suspicion or documentation of central nervous system (CNS) disease.",
                "criterions": [
                    {
                        "exact_snippets": "Clinical suspicion or documentation of central nervous system (CNS) disease",
                        "criterion": "central nervous system (CNS) disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Clinical suspicion or documentation of central nervous system (CNS) disease",
                        "criterion": "central nervous system (CNS) disease",
                        "requirement": {
                            "requirement_type": "evidence",
                            "expected_value": [
                                "clinical suspicion",
                                "documentation"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Second malignancy, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, or other malignancies for which patients are not on active anticancer therapies and have had no evidence of active malignancy for at least 1 year. Other exceptions may be considered with sponsor approval. Previous hormonal therapy with luteinizing hormone-releasing hormone agonists for prostate cancer and treatment with bisphosphonates and receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors are not criteria for exclusion.",
                "criterions": [
                    {
                        "exact_snippets": "Second malignancy, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, or other malignancies for which patients are not on active anticancer therapies and have had no evidence of active malignancy for at least 1 year.",
                        "criterion": "second malignancy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Second malignancy, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, or other malignancies for which patients are not on active anticancer therapies and have had no evidence of active malignancy for at least 1 year.",
                        "criterion": "second malignancy",
                        "requirement": {
                            "requirement_type": "exceptions",
                            "expected_value": [
                                "treated basal cell skin carcinoma",
                                "localized squamous skin carcinoma",
                                "localized prostate cancer",
                                "other malignancies for which patients are not on active anticancer therapies and have had no evidence of active malignancy for at least 1 year"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "patients are not on active anticancer therapies",
                        "criterion": "active anticancer therapy",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "no evidence of active malignancy for at least 1 year",
                        "criterion": "active malignancy",
                        "requirement": {
                            "requirement_type": "evidence of activity",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "no evidence of active malignancy for at least 1 year",
                        "criterion": "active malignancy",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Other exceptions may be considered with sponsor approval.",
                        "criterion": "sponsor approval for exceptions",
                        "requirement": {
                            "requirement_type": "approval",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Previous hormonal therapy with luteinizing hormone-releasing hormone agonists for prostate cancer and treatment with bisphosphonates and receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors are not criteria for exclusion.",
                        "criterion": "previous hormonal therapy for prostate cancer",
                        "requirement": {
                            "requirement_type": "exclusion",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "treatment with bisphosphonates and receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors are not criteria for exclusion.",
                        "criterion": "treatment with bisphosphonates or RANKL inhibitors",
                        "requirement": {
                            "requirement_type": "exclusion",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Considered eligible to receive autologous or allogeneic stem cell transplant (SCT) at the time of enrollment.",
                "criterions": [
                    {
                        "exact_snippets": "Considered eligible to receive autologous or allogeneic stem cell transplant (SCT) at the time of enrollment.",
                        "criterion": "eligibility for stem cell transplant",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Considered eligible to receive autologous or allogeneic stem cell transplant (SCT) at the time of enrollment.",
                        "criterion": "eligibility for stem cell transplant",
                        "requirement": {
                            "requirement_type": "type of transplant",
                            "expected_value": [
                                "autologous",
                                "allogeneic"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Considered eligible to receive autologous or allogeneic stem cell transplant (SCT) at the time of enrollment.",
                        "criterion": "eligibility for stem cell transplant",
                        "requirement": {
                            "requirement_type": "time",
                            "expected_value": "at the time of enrollment"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Known inherited or acquired bleeding disorders.",
                "criterions": [
                    {
                        "exact_snippets": "Known inherited or acquired bleeding disorders.",
                        "criterion": "bleeding disorders",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known inherited or acquired bleeding disorders.",
                        "criterion": "bleeding disorders",
                        "requirement": {
                            "requirement_type": "origin",
                            "expected_value": [
                                "inherited",
                                "acquired"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Acute active infection requiring systemic antibiotics, antiviral (except antiviral therapy directed against reactivation) or antifungal agents within 14 days prior to enrollment.",
                "criterions": [
                    {
                        "exact_snippets": "Acute active infection requiring systemic antibiotics, antiviral ... or antifungal agents within 14 days prior to enrollment.",
                        "criterion": "acute active infection",
                        "requirement": {
                            "requirement_type": "treatment requirement",
                            "expected_value": [
                                "systemic antibiotics",
                                "antiviral agents",
                                "antifungal agents"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Acute active infection requiring systemic antibiotics, antiviral ... or antifungal agents within 14 days prior to enrollment.",
                        "criterion": "acute active infection",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to enrollment"
                            }
                        }
                    },
                    {
                        "exact_snippets": "antiviral (except antiviral therapy directed against reactivation)",
                        "criterion": "antiviral therapy",
                        "requirement": {
                            "requirement_type": "exclusion",
                            "expected_value": "antiviral therapy directed against reactivation"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Glucocorticoid therapy (prednisone > 40 mg/day or equivalent) within 14 days prior to enrollment; corticosteroid therapy for hypercalcemia is allowed.",
                "criterions": [
                    {
                        "exact_snippets": "Glucocorticoid therapy (prednisone > 40 mg/day or equivalent) within 14 days prior to enrollment",
                        "criterion": "glucocorticoid therapy",
                        "requirement": {
                            "requirement_type": "drug",
                            "expected_value": [
                                "prednisone",
                                "equivalent glucocorticoid"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Glucocorticoid therapy (prednisone > 40 mg/day or equivalent) within 14 days prior to enrollment",
                        "criterion": "glucocorticoid therapy",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 40,
                                "unit": "mg/day"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Glucocorticoid therapy (prednisone > 40 mg/day or equivalent) within 14 days prior to enrollment",
                        "criterion": "glucocorticoid therapy",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 14 days prior to enrollment"
                        }
                    },
                    {
                        "exact_snippets": "corticosteroid therapy for hypercalcemia is allowed",
                        "criterion": "corticosteroid therapy for hypercalcemia",
                        "requirement": {
                            "requirement_type": "indication",
                            "expected_value": "hypercalcemia"
                        }
                    },
                    {
                        "exact_snippets": "corticosteroid therapy for hypercalcemia is allowed",
                        "criterion": "corticosteroid therapy for hypercalcemia",
                        "requirement": {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Significant neuropathy (Grade 3 to 4, or Grade 2 with pain) within 14 days prior to enrollment.",
                "criterions": [
                    {
                        "exact_snippets": "Significant neuropathy (Grade 3 to 4, or Grade 2 with pain) within 14 days prior to enrollment.",
                        "criterion": "neuropathy",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": [
                                "Grade 3",
                                "Grade 4"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Significant neuropathy (Grade 3 to 4, or Grade 2 with pain) within 14 days prior to enrollment.",
                        "criterion": "neuropathy",
                        "requirement": {
                            "requirement_type": "severity_with_pain",
                            "expected_value": "Grade 2 with pain"
                        }
                    },
                    {
                        "exact_snippets": "Significant neuropathy (Grade 3 to 4, or Grade 2 with pain) within 14 days prior to enrollment.",
                        "criterion": "neuropathy",
                        "requirement": {
                            "requirement_type": "time_window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to enrollment"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Significant disease or medical conditions, as assessed by the investigator and sponsor, that would substantially increase the risk-benefit ratio of participating in the study. This includes, but is not limited to, acute myocardial infarction within the last 6 months, unstable angina, uncontrolled diabetes mellitus, significant active infections, congestive heart failure, or New York Heart Association (NYHA) Class III or IV heart failure.",
                "criterions": [
                    {
                        "exact_snippets": "Significant disease or medical conditions, as assessed by the investigator and sponsor, that would substantially increase the risk-benefit ratio of participating in the study.",
                        "criterion": "significant disease or medical conditions",
                        "requirement": {
                            "requirement_type": "risk-benefit ratio impact",
                            "expected_value": "would substantially increase"
                        }
                    },
                    {
                        "exact_snippets": "acute myocardial infarction within the last 6 months",
                        "criterion": "acute myocardial infarction",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "unstable angina",
                        "criterion": "unstable angina",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled diabetes mellitus",
                        "criterion": "diabetes mellitus",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "significant active infections",
                        "criterion": "active infections",
                        "requirement": {
                            "requirement_type": "significance",
                            "expected_value": "significant"
                        }
                    },
                    {
                        "exact_snippets": "congestive heart failure",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "New York Heart Association (NYHA) Class III or IV heart failure",
                        "criterion": "NYHA heart failure class",
                        "requirement": {
                            "requirement_type": "class",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Known active or chronic hepatitis B or C infection or human immunodeficiency virus (HIV) infection in medical history.",
                "criterions": [
                    {
                        "exact_snippets": "Known active or chronic hepatitis B or C infection",
                        "criterion": "hepatitis B infection",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "chronic"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Known active or chronic hepatitis B or C infection",
                        "criterion": "hepatitis C infection",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "chronic"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "human immunodeficiency virus (HIV) infection in medical history",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "medical history presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_miscellaneous": []
}